Nextrials' Prism Achieves Compliance Certification
San Ramon, CA-April 6, 2009-Nextrials, Inc., a leader in clinical research software and services, today announced that its award-winning Prism® data capture and clinical trial management platform has achieved certification for compliance with federally recognized Healthcare Information Technology Standards Panel (HITSP) Interoperability Specifications. The company successfully completed compliance testing at the 10th Annual IHE North America Connectathon by demonstrating Prism’s integration of its electronic data capture (EDC) platform used in clinical trials with platforms used by healthcare organizations to maintain electronic health records (EHR) for patients.
Administered by the American National Standards Institute (ANSI), HITSP is a cooperative effort with strategic partners such as the Healthcare Information and Management Systems Society (HIMSS), Integrating the Healthcare Enterprise (IHE), Advanced Technology Institute (ATI) and Booz Allen Hamilton.
Nextrials is again demonstrating Prism’s interoperability at the HIMSS 2009 Interoperability Showcase, part of the 2009 Annual Healthcare Information and Management Systems Society’s Conference & Exhibition, being held April 4-8 in Chicago. Conference attendees can find the showcase in Booth 7750 in the North Hall of McCormick Place.
“Nextrials has dedicated a significant amount of time toward support for ANSI’s work to promote the development and adoption of HITSP standards,” explained James Rogers, CEO and co-founder of Nextrials. “As an early implementer of HITSP interoperability specifications, we recognize the value of integrating electronic health records within clinical trial management systems, which will advance the continuum of patient care and further future clinical research.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
